[11C]PIB in a nondemented population
Potential antecedent marker of Alzheimer disease
Abstract
Background: Beta-amyloid (Aβ) plaques are the hallmark of Alzheimer disease (AD). A PET imaging tracer that binds to Aβ plaques in vivo, N-methyl-[11C]2-(4′-methylaminophenyl)-6-hydroxybenzothiazole (or [11C]PIB for "Pittsburgh Compound-B"), has significantly higher binding in subjects diagnosed with dementia of the Alzheimer type (DAT) compared to nondemented controls. The authors used this imaging technique to investigate whether abnormal binding occurs in clinically normal individuals, prior to the development of cognitive changes.
Methods: Forty-one nondemented subjects (age range 20 to 86 years) and 10 patients with DAT (age range 66 to 86 years) underwent [11C]PIB PET scanning. Regions of interest were drawn on the MRI over the cerebellar, prefrontal, lateral temporal, occipital, gyrus rectus, precuneus, and striatal cortex. Binding potential values (BPs), proportional to the density of [11C]PIB-Aβ binding sites, were calculated using the Logan graphical analysis and the cerebellar cortex for a reference tissue.
Results: Patients with DAT had elevated BP values vs nondemented subjects (p < 0.0001). Four of the 41 nondemented subjects had elevated cortical BP values and their BP values as a group were not significantly different from the DAT subjects' BP values. Two of these four nondemented subjects had [11C]PIB uptake, both visually and quantitatively, that was indistinguishable from the DAT subjects.
Conclusions: Elevated [11C]PIB binding in nondemented subjects suggests that [11C]PIB amyloid imaging may be sensitive for detection of a preclinical Alzheimer disease state. Longitudinal studies will be required to determine the association of elevated [11C]PIB binding and risk of developing dementia of the Alzheimer type.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
References
1.
Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 2001;21:RC189.
2.
Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002;10:24–35.
3.
Kung MP, Hou C, Zhuang ZP, et al. IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res 2002;956:202–210.
4.
Zhuang ZP, Kung MP, Wilson A, et al. Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain. J Med Chem 2003;46:237–243.
5.
Wang Y, Klunk WE, Huang GF, Debnath ML, Holt DP, Mathis CA. Synthesis and evaluation of 2-(3′-iodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease. J Mol Neurosci 2002;19:11–16.
6.
Okamura N, Suemoto T, Shimadzu H, et al. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci 2004;24:2535–2541.
7.
Shimadzu H, Suemoto T, Suzuki M, et al. Novel probes for imaging amyloid-β: F-18 and C-11 labeling of 2-(4-aminostyryl)benzoxazole derivatives. J Label Compd Radiopharm 2004;47:181–190.
8.
Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740–2754.
9.
Verhoef N, Wilson AA, Takeshita S, et al. In vivo imaging of Alzheimer disease β-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 2004;12:584–595.
10. ix.
Klunk WE, Engler H, Nordberg A, et al. Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clin N Am 2003;13:781–789,
11.
Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–319.
12.
Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999;45:358–368.
13.
Troncoso JC, Martin LJ, Dal Forno G, Kawas CH. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging 1996;17:365–371.
14.
Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998;57:1168–1174.
15.
Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. "Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology 2000;55:370–376.
16.
Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351–357.
17.
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412–2414.
18.
Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988;24:637–639.
19.
Berg L, McKeel DW, Jr., Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326–335.
20.
Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985–1992.
21.
Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58:397–405.
22.
Buckner RL, Head D, Parker J, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage 2004;23:724–738.
23.
Accorsi R, Adam LE, Werner ME, Karp JS. Optimization of a fully 3D single scatter simulation algorithm for 3D PET. Phys Med Biol 2004;49:2577–2598.
24.
Snyder AZ. Difference image vs ratio image error function forms in PET-PET realignment. In: Myer R, Cunningham VJ, Bailey DL, Jones T, eds. Quantification of brain function using PET. San Diego: Academic Press, 1996:131–137.
25.
Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 1992;16:620–633.
26.
Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 1993;17:536–546.
27.
Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme Medical, 1998.
28.
Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709–7717.
29.
Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990;10:740–747.
30.
Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834–840.
31.
Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 1989;135:309–319.
32.
Price JC, Klunk WE, Lopresti BJ, et al. Quantitative PIB PET imaging studies of amyloid deposition in subjects with Alzheimer's disease, mild cognitive impairment, and healthy controls. Neuroimage 2004;22:T49.
33.
Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005;46:1959–1972.
34.
Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984;15:217–227.
35.
Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528–1547.
36.
Ichise M, Meyer JH, Yonekura Y. An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 2001;42:755–763.
37.
Logan J, Fowler JS, Volkow ND, Ding YS, Wang GJ, Alexoff DL. A strategy for removing the bias in the graphical analysis method. J Cereb Blood Flow Metab 2001;21:307–320.
38.
Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci USA 2001;98:676–682.
39.
Wheeler ME, Buckner RL. Functional-anatomic correlates of remembering and knowing. Neuroimage 2004;21:1337–1349.
40.
Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003;23:2086–2092.
41.
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
42.
Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology 1988;38:900–903.
43.
Thurstone LL, Thurstone LG. Examiner manual for the SRA Primary Mental Abilities Test. Chicago: Science Research Associates, 1949.
44.
Armitage SG. An analysis of certain psychological tests used in the evaluation of brain injury. Psych Mono 1946;60:1–48.
45.
Wechsler D. Manual: Wechsler Adult Intelligence Scale. New York: Psychological Corporation, 1955.
46.
Tomlinson BE, Blessed G, Roth M. Observations on the brains of non-demented old people. J Neurol Sci 1968;7:331–356.
47.
Katzman R, Terry R, DeTeresa R, et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988;23:138–144.
48.
Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239–259.
Information & Authors
Information
Published In
Copyright
© 2006.
Publication History
Published online: August 7, 2006
Published in print: August 8, 2006
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Normal-Tension Glaucoma and Potential Clinical Links to Alzheimer’s Disease, Journal of Clinical Medicine, 13, 7, (1948), (2024).https://doi.org/10.3390/jcm13071948
- Deep Learning-Driven Estimation of Centiloid Scales from Amyloid PET Images with 11C-PiB and 18F-Labeled Tracers in Alzheimer’s Disease, Brain Sciences, 14, 4, (406), (2024).https://doi.org/10.3390/brainsci14040406
- Associations of sleep disorders with all-cause MCI/dementia and different types of dementia – clinical evidence, potential pathomechanisms and treatment options: A narrative review, Frontiers in Neuroscience, 18, (2024).https://doi.org/10.3389/fnins.2024.1372326
- LAM Test: A New Cognitive Marker for Early Detection in Preclinical Alzheimer’s Disease, Journal of Alzheimer’s Disease, 100, 3, (1039-1053), (2024).https://doi.org/10.3233/JAD-240067
- Plasma Neurofilament Light Relates to Divergent Default and Salience Network Connectivity in Alzheimer’s Disease and Behavioral Variant Frontotemporal Dementia, Journal of Alzheimer’s Disease, 99, 3, (965-980), (2024).https://doi.org/10.3233/JAD-231251
- Cancer Immunotherapy and Medical Imaging Research Trends from 2003 to 2023: A Bibliometric Analysis, Journal of Multidisciplinary Healthcare, Volume 17, (2105-2120), (2024).https://doi.org/10.2147/JMDH.S457367
- Higher amyloid is associated with greater loneliness among cognitively normal older adults during the COVID-19 pandemic, F1000Research, 11, (1134), (2024).https://doi.org/10.12688/f1000research.124891.2
- Exploring easily accessible neurophysiological biomarkers for predicting Alzheimer’s disease progression: a systematic review, Alzheimer's Research & Therapy, 16, 1, (2024).https://doi.org/10.1186/s13195-024-01607-4
- The Association Between Postural Sway and Preclinical Alzheimer Disease Among Community-Dwelling Older Adults, The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 79, 7, (2024).https://doi.org/10.1093/gerona/glae091
- Aberrant functional connectivity between the retrosplenial cortex and hippocampal subregions in amnestic mild cognitive impairment and Alzheimer’s disease, Brain Communications, 7, 1, (2024).https://doi.org/10.1093/braincomms/fcae476
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.